Abstract
Arsenic trioxide (As2O3) has been widely accepted as the second-best choice for the treatment of relapsed and refractory acute promyelocytic leukemia (APL) patients. However, a few studies have been conducted on a detailed speciation of As2O3 metabolites in blood samples of patients. To clarify the speciation of arsenic, the blood samples were collected at various time points from a patient with APL after remission induction therapy and during consolidation therapy. The total amounts of arsenic in blood cells and plasma, and the plasma concentrations of inorganic arsenic and methylated metabolites were determined by inductively coupled plasma mass spectrometry (ICP-MS) and high-performance liquid chromatography/ICP-MS, respectively. The total amounts of arsenic in the blood cells were 4–10 times higher than those in plasma. Among all arsenic metabolites, the pentavalent arsenate (AsV) in plasma was more readily eliminated. During the drug-withdrawal period, the initial plasma concentrations of trivalent arsenic (AsIII) declined more rapidly than those of methylarsonic acid and dimethlyarsinic acid, which are known as the major methylated metabolites of AsIII. On the other hand, during the consecutive administration in the consolidation therapy period, the plasma concentrations of total arsenic and arsenic metabolites increased with time. In conclusion, these results may support the idea that methylated metabolites of As2O3 contribute to the efficacy of arsenic in APL patients. These results also suggest that detailed studies on the pharmacokinetics as well as the pharmacodynamics of As2O3 in the blood cells from APL patients should be carried out to provide an effective treatment protocol.
Similar content being viewed by others
References
Goddard AD, Borrow J, Freemont PS, Solomon E (1991) Science 254:1371–1374
Tong JH, Dong S, Geng JP, Huang W, Wang ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ, Berger R (1992) Oncogene 7:311–316
de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A (1990) Nature 347:558–561
Melnick A, Licht JD (1999) Blood 93:3167–3215
Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH (1999) Blood 93:4131–4143
Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Blood 89:3354–3360
Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) N Engl J Med 339:1341–1348
Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O’Leary JJ, White RM, Williams GA, Pazdur R (2001) Oncologist 6:4–11
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R (2002) Leukemia 16:617–622
Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr (2001) J Clin Oncol 19:3852–3860
Aposhian HV (1997) Annu Rev Pharmacol Toxicol 37:397–419
Kitchin KT (2001) Toxicol Appl Pharmacol 172:249–261
Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Toxicol Appl Pharmacol 174:282–293
Aposhian HV, Gurzau ES, Le XC, Gurzau A, Healy SM, Lu X, Ma M, Yip L, Zakharyan RA, Maiorino RM, Dart RC, Tircus MG, Gonzalez-Ramirez D, Morgan DL, Avram D, Aposhian MM (2000) Chem Res Toxicol 13:693–697
Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Chem Res Toxicol 17:95–103
Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ (2000) Arch Toxicol 74:289–299
Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S (2003) Cancer Res 63:1853–1859
Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML (2004) Toxicol Appl Pharmacol 198:327–335
Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S (2006) Biol Pharm Bull 29:1022–1027
Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T, Ohnishi K (2007) Cancer Chemother Pharmacol 59:485–493
Shibata Y, Yoshinaga J, Morita M (1994) Appl Organomet Chem 8:249–251
Douer D, Tallman MS (2005) J Clin Oncol 23:2396–2410
Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H (2003) J Clin Oncol 21:2326–2334
Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A, Madelaine-Chambrin I, Cimerman P, Chevret S, Hermine O, Dombret H, Claude Brouet J, Paul Fermand J (2004) Leukemia 18:1518–1521
Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Blood 98:266–271
Lu M, Wang H, Li XF, Lu X, Cullen WR, Arnold LL, Cohen SM, Le XC (2004) Chem Res Toxicol 17:1733–1742
Benramdane L, Accominotti M, Fanton L, Malicier D, Vallon JJ (1999) Clin Chem 45:301–306
Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P (2008) Anal Chim Acta 607:83–91
Naranmandura H, Suzuki KT (2008) Toxicol Appl Pharmacol 227:390–399
Acknowledgements
This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology and by the Promotion and Mutual Aid Corporation for Private Schools of Japan. We acknowledge Nippon Shinyaku Co. Ltd. for generous supply of Trisenox®.
Author information
Authors and Affiliations
Corresponding authors
Electronic supplementary material
Below is the link to the electronic supplementary material.
Table S1
Analytical Conditions of ICP-MS (PDF 14.05 KB)
Rights and permissions
About this article
Cite this article
Yoshino, Y., Yuan, B., Miyashita, Si. et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393, 689–697 (2009). https://doi.org/10.1007/s00216-008-2487-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00216-008-2487-9